Salivary duct carcinoma

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| Salivary duct carcinoma | |
|---|---|
| Synonyms | SDC |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Swelling in the salivary gland, pain, facial nerve dysfunction |
| Complications | Metastasis, facial nerve paralysis |
| Onset | Typically in adulthood |
| Duration | Chronic |
| Types | Primary tumor, metastatic |
| Causes | Genetic mutations, radiation exposure |
| Risks | Smoking, radiation therapy |
| Diagnosis | Biopsy, imaging studies |
| Differential diagnosis | Mucoepidermoid carcinoma, adenoid cystic carcinoma |
| Prevention | Avoidance of risk factors |
| Treatment | Surgery, radiation therapy, chemotherapy |
| Medication | Chemotherapeutic agents |
| Prognosis | Generally poor prognosis |
| Frequency | Rare |
| Deaths | High mortality rate |
Salivary Duct Carcinoma (SDC) is a rare and aggressive form of cancer that originates in the ducts of the salivary glands. It is known for its rapid growth, potential to metastasize, and a high rate of recurrence. This malignancy represents a significant challenge in terms of diagnosis and management, making it a critical subject of study in the field of oncology and head and neck surgery.
Epidemiology[edit]
SDC is uncommon, accounting for less than 10% of all salivary gland neoplasms. It predominantly affects older adults, with a higher incidence in males than in females. The most common site for SDC is the parotid gland, followed by the submandibular gland and minor salivary glands scattered throughout the mucosa of the mouth and throat.
Etiology[edit]
The exact cause of SDC is not well understood. However, several risk factors have been identified, including prior radiation exposure to the head and neck region, smoking, and certain genetic predispositions. It is also associated with mutations in oncogenes and tumor suppressor genes, although the specific pathways involved are still under investigation.
Clinical Presentation[edit]
Patients with SDC typically present with a rapidly enlarging mass in the affected salivary gland. Pain, facial nerve palsy, and skin involvement may also be observed, indicating a more advanced disease. Due to its aggressive nature, SDC may metastasize to regional lymph nodes and distant organs, such as the lungs and bones, at the time of diagnosis.
Diagnosis[edit]
The diagnosis of SDC involves a combination of clinical examination, imaging studies, and histopathological analysis. Imaging techniques such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) are used to assess the extent of the disease. Fine-needle aspiration (FNA) biopsy or open biopsy is performed to obtain tissue samples for histological examination, which is crucial for confirming the diagnosis.
Treatment[edit]
The mainstay of treatment for SDC is surgical resection with clear margins, often accompanied by neck dissection to address regional lymph node metastasis. Adjuvant radiation therapy is recommended in cases of high-risk features, such as perineural invasion, lymphovascular invasion, and positive surgical margins. The role of chemotherapy is still being explored, with some evidence supporting its use in metastatic or unresectable disease.
Prognosis[edit]
The prognosis of SDC is generally poor, with a high rate of local recurrence and distant metastasis. The overall survival rate varies, but it is significantly lower compared to other salivary gland tumors. Factors that negatively impact prognosis include advanced stage at diagnosis, high-grade histology, and the presence of lymph node involvement.
Research and Future Directions[edit]
Ongoing research is focused on understanding the molecular mechanisms underlying SDC, which may lead to the development of targeted therapies. Clinical trials are also underway to evaluate the efficacy of novel therapeutic agents and treatment strategies.
See Also[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian